GLAXOSMITHKLINE PLC Form 6-K August 12, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending August 2014

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc (GSK) was advised on 12 August 2014 that the following Directors, Persons Discharging Managerial Responsibility and Connected Person acquired GSK Ordinary Shares on 11 August 2014, at a price of 1378.19 pence per Ordinary Share, through GSK's ShareReward Plan:

Director/PDMR	Shares under the	Number of Ordinary Shares under the n matching element of the plan (GSK contribution)
Sir Andrew Witty	9	9
Mr S M Bicknell	9	9
Mr R G Connor	9	9
Mr S Dingemans	9	9
Mr D S Redfern	9	9
Ms C Thomas	9	9
Mr P C Thomson	8	8
Dr P J T Vallance	10	10
Ms E Walmsley	9	9
Mrs V A Whyte	9	9
Connected person	Number of Ordina Shares under the personal contribu- element of the pla	Shares under the matching element of the
Mrs K Thomson (Connected person of Mr P C Thomson)		2

V A Whyte Company Secretary 12 August 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GlaxoSmithKline plc (Registrant)

Date: August 12, 2014

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on

behalf of GlaxoSmithKline plc